alpha7 nicotinic acetylcholine (nACh7) receptors are predominantly expressed in the CNS, including the hippocampus, cortex and ventral tegmental area. Nicotinic ACh7 receptors are involved with LTP, memory and attention deficits and so are drug development targets for diseases of cognition including Alzheimer’s and schizophrenia. The nACh7 receptors are rapidly desensitized, have homopentameric architecture and respond to agonists including nicotine, acetylcholine, AR-R17779 and epibatidine. In addition the currents are blocked by the competitive antagonist methyllycaconitine. Drug discovery efforts have also identified positive allosteric modulators such as PNU-120596 which increase the potency of activators such as acetylcholine without causing desensitization. This cell line also expresses the ric3 chaperone protein as when co-expressed with the nACh7 receptor, ric-3 significantly increases surface expression.